Loading…
Loading…
As your customers implement AI, do you view this as a threat or as an opportunity?
If that continues to take hold, what instruments would you expect to be the first to participate in that recovery?
are there any updates on your xF FDA submission? I know it was reiterated that it was submitted
can you discuss the strategic value of the added capability when samples are QNS?
could you share any updates on your work on the foundation model with AstraZeneca and Pathos
as you think about the possibility of moving your Insights business into other areas than cancer
could you remind us the assumption baked in on gross margin and ASP improvement if you do receive MolDx xM reimbursement
what is embedded in your 2025 guidance, if anything for this year?
where are you in the process of how BD manages discounting? How is this driving you towards your eventual pricing goals?
Can you give us your latest thoughts on how you see growth potential in that market?
what does operating margin progression look like this year with the addition to BD? What prudence is in those risk-adjusted assumption